AI pipeline and biomarkers to define at risk populations for liver cancer development and for treatment response prediction.

Novel, socially accepted and affordable treatments to revert ICI resistance in HCC and chemoresistance in HB.

Evidence-based recommendations for policy makers and health professionals.